Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021 02; 14(2):143-148.. View in PubMed
  • Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. Haemophilia. 2021 Jan; 27(1):164-172.. View in PubMed
  • Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child. Pediatrics. 2020 11; 146(5).. View in PubMed
  • Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.. View in PubMed
  • Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thromb Haemost. 2021 Mar; 121(3):351-360.. View in PubMed
  • Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv. 2020 10 13; 4(19):4632-4639.. View in PubMed
  • Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock. Pediatr Blood Cancer. 2020 12; 67(12):e28731.. View in PubMed
  • Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children’s Hospital-Acquired Thrombosis Consortium. J Pediatr. 2021 01; 228:252-259.e1.. View in PubMed
  • Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost. 2020 Oct; 4(7):1101-1113.. View in PubMed
  • Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation. J Thromb Haemost. 2020 09; 18(9):2205-2208.. View in PubMed